Crystalline silicon nanomembrane (Si NM) is promising in wearable and implantable bioelectronics due to its electrical and mechanical performances. However, the current explorations are not enough to firmly bridge ultrathin encapsulation strategies with high performance crystalline Si NM based transistors. In this work, we utilized Al2O3/alucone as the ultrathin encapsulation strategies aim to thoroughly investigate the effect of gate dielectric surface area on the electrical performance of crystalline Si NM based metal-oxide-semiconductor capacitors (MOSCAPs). The comparative analysis was implemented on the three types of diameters (Ø) MOSCAPs with and without Al2O3/alucone encapsulation under planar and concave/convex bending conditions. Benefited from the Al2O3/alucone ultrathin encapsulations, the stability of gate leakage current density, and interfacial characteristics were maintained and improved under mechanical bending deformations for MOSCAPs with predefined Ø of 160, 240, and 320 μm compared to the bare MOSCAPs. Combined with the Ø-related mechanical analysis on the maximum strain in the critical layers and the practical measurements, the encapsulated MOSCAPs with Ø 160 μm showed the most stable electro-mechanical performances. The variations for encapsulated MOSCAPs with three types of Ø emerged in the oxide layer and the interface at dielectric/Si NM that were carefully evaluated according to the bending deformations. These findings are significant for leveraging the practical applications in the ultrathin encapsulation strategies for reliable operations of crystalline Si NM based integrated circuits (ICs).

The microstructure evolution of SCM435 cold heading steel at different cooling rates was investigated by means of scanning electron microscopy, TEM, XRD, and electron backscatter diffraction. The results show that the cooling rate has a significant effect on the microstructure of the experimental steel. With an acceleration of the cooling, the microstructure of the steel gradually changed from ferrite and pearlite to ferrite, pearlite, and granular bainite; finally, the pearlite disappeared, and the microstructure changed to acicular ferrite, bainite, and martensite. With an increase in the cooling rate, the morphology of the carbide underwent an evolution from sheet carbide to short-rod carbide, granular carbide, and ultimately thin-strip carbide. With the acceleration of cooling, the proportion of large-angle grain boundaries gradually decreased, and the area of small-angle grain boundaries gradually increased. When the cooling rate was 0.1℃/s, the proportion of large-angle grain boundaries was as high as 52.8%, and the dislocation density was only 1.91 × 1012 cm−2. When the cooling rate was 2.0℃/s, the proportion of large-angle grain boundaries was only 27.1%, and dislocation density increased to 5.38 × 1012 cm−2. With the increase in the cooling rate, the depth of the decarbonization layer and the thickness of the scale oxide gradually decreased, the proportion of FeO phase in the scale phase gradually decreased, and the proportion of Fe3O4 phase and Fe2O3 phase gradually increased. The tensile strength increased monotonously with the increase in cooling rate, whereas the elongation and shrinkage first decreased, then increased, and then decreased. When the cooling rate was 1.0 m/s, the short rod and granular bainite in the material structure endowed the SCM435 steel with excellent strength and toughness matching, and the tensile strength and elongation of the steel reached 895 MPa and 24%, respectively.

Early stable deep molecular response (DMR) of nilotinib is associated with goal of treatment-free remission (TFR) for patients with chronic-phase chronic myeloid leukemia (CML-CP). It is significant to early distinguish patients who can obtain DMR and fit for TFR. We performed a multicenter study to explore early cumulative MR4.5 rate by 18 months with nilotinib in patients with newly diagnosed CML-CP (ND-CML-CP) in China. From 29 institutes, 106 ND-CML-CP patients received nilotinib (300mg BID). The cumulative MR4.5 rate of nilotinib by 18 months was 69.8% (74/106). The cumulative MMR and MR4.0 rates of nilotinib by 18 months were 94.3% (100/106) and 84.9% (90/106), respectively. Patients with ultra-early molecular response (u-EMR) at 6 weeks were not significantly different to obtain DMR or MMR by 24 months compared to those without u-EMR (P=0.7584, P=0.9543, respectively). Our study demonstrated that treatment with nilotinib in patients with ND-CML-CP contributed to obtain high early MR4.5.